Clinical Trial Update: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments [Phase 2]

View source ↗

Summary

A Phase 2 study assessing alpelisib with either fulvestrant or letrozole in PIK3CA-mutant, HR+, HER2-negative advanced breast cancer that progressed after prior…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• Faslodex (fulvestrant)
• Piqray (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-03-27